Figure 3

Correlation between trough drug levels (sunitinib and SU12662, combined) and the intrapatient changes in sVEGFR-2 (panel a) and sVEGFR-3 (panel b) plasma levels during first and second treatment cycles. (Symbols: О = C1D28; Δ = C2D28)